These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 28137213)
1. Docking and QSAR Studies of 1,4-Dihydropyridine Derivatives as Anti- Cancer Agent. Mollazadeh S; Shamsara J; Iman M; Hadizadeh F Recent Pat Anticancer Drug Discov; 2017; 12(2):174-185. PubMed ID: 28137213 [TBL] [Abstract][Full Text] [Related]
2. Quantitative structure-activity relationship and quantitative structure-pharmacokinetics relationship of 1,4-dihydropyridines and pyridines as multidrug resistance modulators. Zhou XF; Shao Q; Coburn RA; Morris ME Pharm Res; 2005 Dec; 22(12):1989-96. PubMed ID: 16158213 [TBL] [Abstract][Full Text] [Related]
3. 3D-QSAR (CoMFA, CoMSIA) and Molecular Docking Studies on Histone Deacetylase 1 Selective Inhibitors. Abdizadeh T; Ghodsi R; Hadizadeh F Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):365-383. PubMed ID: 28482791 [TBL] [Abstract][Full Text] [Related]
4. Application of GA-MLR for QSAR Modeling of the Arylthioindole Class of Tubulin Polymerization Inhibitors as Anticancer Agents. Ahmadi S; Habibpour E Anticancer Agents Med Chem; 2017; 17(4):552-565. PubMed ID: 27528182 [TBL] [Abstract][Full Text] [Related]
5. Cytotoxic and multidrug resistance reversal activities of novel 1,4-dihydropyridines against human cancer cells. Shekari F; Sadeghpour H; Javidnia K; Saso L; Nazari F; Firuzi O; Miri R Eur J Pharmacol; 2015 Jan; 746():233-44. PubMed ID: 25445037 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and 3D-QSAR study of 1,4-dihydropyridine derivatives as MDR cancer reverters. Radadiya A; Khedkar V; Bavishi A; Vala H; Thakrar S; Bhavsar D; Shah A; Coutinho E Eur J Med Chem; 2014 Mar; 74():375-87. PubMed ID: 24486418 [TBL] [Abstract][Full Text] [Related]
7. Dihydropyridine derivatives to overcome atypical multidrug resistance: design, synthesis, QSAR studies, and evaluation of their cytotoxic and pharmacological activities. Mehdipour AR; Javidnia K; Hemmateenejad B; Amirghofran Z; Miri R Chem Biol Drug Des; 2007 Oct; 70(4):337-46. PubMed ID: 17937779 [TBL] [Abstract][Full Text] [Related]
8. A study on quantitative structure-activity relationship and molecular docking of metalloproteinase inhibitors based on L-tyrosine scaffold. Abbasi M; Ramezani F; Elyasi M; Sadeghi-Aliabadi H; Amanlou M Daru; 2015 Apr; 23(1):29. PubMed ID: 25925871 [TBL] [Abstract][Full Text] [Related]
9. Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation. Abbasi M; Sadeghi-Aliabadi H; Amanlou M Daru; 2017 Jun; 25(1):17. PubMed ID: 28666484 [TBL] [Abstract][Full Text] [Related]
10. Modeling calcium channel antagonistic activity of dihydropyridine derivatives using QTMS indices analyzed by GA-PLS and PC-GA-PLS. Mohajeri A; Hemmateenejad B; Mehdipour A; Miri R J Mol Graph Model; 2008 Apr; 26(7):1057-65. PubMed ID: 17959402 [TBL] [Abstract][Full Text] [Related]
12. Synthesis, Docking Simulation, Biological Evaluations and 3D-QSAR Study of 1,4-Dihydropyridines as Calcium Channel Blockers. El-Moselhy TF; Sidhom PA; Esmat EA; El-Mahdy NA Chem Pharm Bull (Tokyo); 2017; 65(10):893-903. PubMed ID: 28966273 [TBL] [Abstract][Full Text] [Related]
13. Reduced density gradient as a novel approach for estimating QSAR descriptors, and its application to 1, 4-dihydropyridine derivatives with potential antihypertensive effects. Jardínez C; Vela A; Cruz-Borbolla J; Alvarez-Mendez RJ; Alvarado-Rodríguez JG J Mol Model; 2016 Dec; 22(12):296. PubMed ID: 27889884 [TBL] [Abstract][Full Text] [Related]
14. Rational Design of Colchicine Derivatives as anti-HIV Agents via QSAR and Molecular Docking. Worachartcheewan A; Songtawee N; Siriwong S; Prachayasittikul S; Nantasenamat C; Prachayasittikul V Med Chem; 2019; 15(4):328-340. PubMed ID: 30251609 [TBL] [Abstract][Full Text] [Related]
15. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ). Davis GD; Vasanthi AH Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945 [TBL] [Abstract][Full Text] [Related]
16. Design of potential anti-tumor PARP-1 inhibitors by QSAR and molecular modeling studies. Abbasi-Radmoghaddam Z; Riahi S; Gharaghani S; Mohammadi-Khanaposhtanai M Mol Divers; 2021 Feb; 25(1):263-277. PubMed ID: 32140890 [TBL] [Abstract][Full Text] [Related]
17. Hybrid Docking-QSAR Studies of 1, 4-dihydropyridine-3, 5-Dicarboxamides as Potential Antitubercular Agents. Rasouli Y; Davood A Curr Comput Aided Drug Des; 2018; 14(1):35-53. PubMed ID: 28462696 [TBL] [Abstract][Full Text] [Related]
18. Theoretical studies on 1,4-dihydropyridine derivatives as P-glycoprotein allosteric inhibitors: insights on symmetry and stereochemistry. Mollazadeh S; Hadizadeh F; Ferreira RJ J Biomol Struct Dyn; 2021 Aug; 39(13):4752-4763. PubMed ID: 32573349 [TBL] [Abstract][Full Text] [Related]
19. Molecular Studies on Novel Antitumor Bis 1,4-Dihydropyridine Derivatives Against Lung Carcinoma and their Limited Side Effects on Normal Melanocytes. Mohamed MF; Ibrahim NS; Elwahy AHM; Abdelhamid IA Anticancer Agents Med Chem; 2018; 18(15):2156-2168. PubMed ID: 30338746 [TBL] [Abstract][Full Text] [Related]
20. Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques. Roy K; Pratim Roy P Eur J Med Chem; 2009 Jul; 44(7):2913-22. PubMed ID: 19128860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]